Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efavirenz containing antiretroviral regimen · 1 trial · 2 indications
Cmax was obtained directly from the concentration-time data.
Cmin was obtained directly from the concentration-time data.
The AUC(TAU), from time 0 to the time of the last measurable concentration (t), was calculated by the linear trapezoidal rule.
Tmax was obtained directly from the concentration-time data.
| Arm | Type | Description |
|---|---|---|
| EFV600mg Participants With Mild Hepatic Impairment | EXPERIMENTAL | - |
| EFV600mg Participants With Moderate Hepatic Impairment | EXPERIMENTAL | - |
| EFV600mg Participants With Severe Hepatic Impairment | EXPERIMENTAL | - |
| EFV600mg Participants With Normal Hepatic Function | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| efavirenz containing antiretroviral regimen | DRUG | Capsule or Tablet, Oral, once daily for 2 days |
Inclusion Criteria: * HIV-1 infection with or without Hepatitis B or C infection * Stable antiretroviral regimen containing efavirenz and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) for at least 1 month * Mild, moderate or severe hepatic impairment with hepatic cirrhosis Exclusio...
Top 20 of 28 competitors